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Abstract
Background and aim
Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is commonly used to
obtain tissue external to the gastrointestinal tract. EUS-FNA is relatively safe, but occasion-
ally adverse events have been reported. There is scarcity of data on risk factors of adverse
events. The aim of this study is to identify risk factors associated with EUS-FNA.
Methods
In this multicenter case-control study, we retrospectively reviewed 4,097 cases between
2009 and 2012 at 15 hospitals in Korea. Among the patients there were 104 cases (2.5%)
who had adverse events of which 12 (0.29%) were severe. We matched 520 controls (1:5
ratios) stratified by hospital to analyze the potential risk factors.
Results
The most common adverse events were pancreatitis (45/104, 43.3%) and infection (46/104,
44.2%). Endoscopic retrograde cholangiopancreatography (ERCP) on the same day was a
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risk factor of all adverse events [OR = 2.41, 95% CI (1.41, 4.12)], pancreatitis [OR = 2.31,
95% CI (1.02, 5.25)], and infection [OR = 2.75, 95% CI (1.31, 5.78)]. More than 15 to-and-
fro movements during puncture increased the risk of pancreatitis [OR = 2.30, 95% CI (1.11,
4.77)] and infection [OR = 3.65, 95% CI (1.55, 8.59)]. A higher number of punctures was
positively correlated with pancreatitis [OR = 1.34, 95% CI (1.08, 1.67)] but negatively corre-
lated with infection [OR = 0.66, 95% CI (0.48, 0.89)].
Conclusions
EUS-FNA is a safe procedure in which serious adverse events are rare. We define some
risk factors of adverse events during EUS-FNA, including ERCP on the same day, a higher
number of punctures, and more than 15 to-and-fro movements.
Introduction
Endoscopic ultrasound (EUS)-guided tissue sampling is a common method of pathological
diagnosis for lesions around gastrointestinal tract. Frequent targets are the pancreas, peripan-
creatic lymph node, and sub-mucosal tumors [1–8].
To obtain a specimen, the needle must pass through gastrointestinal lumen, which can be
colonized by bacteria, through connective tissue containing blood vessels, and finally reach
aseptic targets. However, adverse events of this procedure are uncommon, occurring in only
about 2.5% [9–13]. Adverse event rates are higher in prospective than in retrospective studies
[11,14]. Adverse events occur more frequently when puncturing pancreatic cysts than solid
masses. There are recommendations to avoid adverse events [9,10,15], but there have been few
studies on risk factors. Most prospective studies failed to collect a sufficient number of adverse
events to analyze risk factors [16–19].
To minimize EUS-guided fine-needle aspiration (EUS-FNA) adverse events, it is important
to define risk factors of adverse events to help endoscopists perform safer diagnostic EUS-
guided tissue sampling. We conducted a multicenter case-control study with a comprehensive
search for adverse events to investigate the risk factors related to EUS-FNA.
Methods
Design, patients and definitions of adverse events
We undertook retrospectively a multicenter case-control study of 15 university-based hospitals
in Korea. At least one investigator from each institution was a member of the EUS study group
in the Korean Society of Gastrointestinal Endoscopy (Seoul, Korea). This study was approved
by the Samsung Medical Center Institutional Review Board (IRB No. 2013-07-119), and the
data were compiled and reported in compliance with the patient confidentiality guidelines.
IRB waived the need for consent and data was accessed anonymously.
First, we reviewed all patients who underwent EUS-guided tissue diagnosis from January
2008 to December 2012 according to consensus definitions of adverse events described below.
We identified 104 cases of adverse events and, classified the cases into six categories: bleeding,
pancreatitis, infection, gastrointestinal perforation, seeding, and other. Bleeding was identified
if hemoglobin decreased by 2 g/dL and an endoscopic or radiological study showed bleeding
related to EUS-FNA or if hemoglobin decreased by 3 g/dL with no specific reason for bleeding
after EUS-FNA. Pancreatitis was diagnosed in patients with a serum amylase level more than
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three times the upper normal limit and significant abdominal pain that started within 24
hours of the EUS-FNA and required intravenous analgesics or fasting. Gastrointestinal per-
foration was diagnosed in patients with abdominal pain and rigidity accompanied by intra-
abdominal free air or equivalent findings with radiological examination. Infection was diag-
nosed in patients with a body temperature increasing from normal to no less than 38.3˚C
after EUS-FNA and who had no other specific cause of high temperature or who had docu-
mented infection related to EUS-FNA. Seeding along the FNA tract was identified if the
tumor developed much more densely near the tract than in other locations or if it was local-
ized along the needle tract without definite evidence of dissemination. We also defined
other adverse events if they were found to be related to EUS-FNA after appropriate evalua-
tions. We defined severe adverse events as those that required surgery, another radiological
or endoscopic intervention, or admission for longer than 4 weeks. We defined categories
and severity at the consensus meeting to find the clinically meaningful events objectively
and consistently under this study setting.
To analyze risk factors, we selected a 1:5 ratio of matched controls stratified by hospital.
Controls were assigned according to a computer-generated random number at Samsung Med-
ical Center (Seoul, Korea). We gathered clinical data and extracted potentially modifiable
details during EUS-FNA procedures. We followed 624 patients until June 2013 and the median
follow up duration was 368 days. The data for 624 EUS-FNAs from all the institutions were
transferred into statistical format at Samsung Medical Center. After a first-pass analysis of all
data, we decided to re-collect missing data from each institution. After such two comprehen-
sive reviews, we analyzed the final data set at Samsung Medical Center.
Data collection for risk factors
Using a standardized clinical record form, we collected comprehensive clinical and endoscopic
information from the patients’ medical records, along with endosonographic photos or videos
taken during the EUS-FNA procedures This data set included demographic characteristics,
experience of the endoscopist, and other procedures on the same day, the nature of the targets,
and endoscopic technical aspects.
All EUS-FNA procedures were performed in inpatient settings and patients were dis-
charged no less than 24 hours after procedures, so it should identify every case of adverse
events.
Statistical analysis
To compare baseline characteristics between cases and controls, we used a t-test for continu-
ous variables and a Chi-square test for categorical variables. We performed univariate and
multivariate analysis to find factors associated with adverse events. For the multivariate analy-
sis, we used 2 models with increasing degrees of adjustment to account for potential confound-
ing factors at baseline. Model 1 was adjusted for age, sex, nature of lesions, and endoscopists’
experience. Model 2 was further adjusted for variables which were statistically significant
(P< 0.05) with univariate analysis for each outcome. To find the risk factor during EUS-FNA
procedures that can be modifined by endoscopists, we also included normal pancreas punc-
ture, distance between endoscopic tip and target, straightening endoscope during puncture,
use of elevator, off-targeting method, vascular puncture, and sonographic finding of bleeding.
Due to the nature of the study design, there were missing variables especially with EUS-FNA
procedures, and we did analysis of these modifiable factors ony with the subjects who had
information about them. All statistical analyses were performed using STATA 12.0.
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Results
Incidence of adverse events
A total of 4,097 EUS-FNA procedures from 15 university-related hospitals. The most common
indication of EUS FNA / tissue acquisition puncture sites were pathology in pancreas (86.5%)
and lymph node (5.8%) (Table 1). We observed 104 (2.5%) adverse events, which included
pancreatitis (n = 45, 43.3%), infection (n = 46, 44.2%), bleeding (n = 8, 7.7%), perforation
(n = 1, 1%), and others (n = 4, 3.9%). The four unclassified adverse events were cholecystitis,
pharyngeal perforation, and two cases of ileus without definite cause. There was no mortality
related to procedure.
Risk factors of adverse events
We compared each complicated case with five matched controls stratified by hospital with
regard to demographic characteristics and potentially modifiable details during EUS-FNA pro-
cedures (Tables 1 and 2). According to the institutions, clinical information, especially about
technical endoscopic details such as straightening of the endoscope, puncture through visible
normal pancreas, and sonographic observation of bleeding, was unavailable for more than
15% of patients. Therefore, we separately analyzed patients (n = 359) who had records of
potentially modifiable details during EUS-FNA procedures (S1 and S2 Tables). For the multi-
variable analysis, we included risk factors considered to be clinically important in previous
studies, such as sex, age, experience of the endoscopist, and the nature of the lesions (cystic or
solid) [9,10,15]. We found several risk factors after the adjustments with model 1 and model 2
as described in statistical analysis of method section (Table 3).
There were some consistent factors which increased the risk of all adverse events, pancreati-
tis and infections. The risk of all adverse events, pancreatitis and infection was higher in
patients with ERCP on the same day. More than 15 to-and-fro movements of the needle car-
ried higher risk in all adverse events, pancreatitis and infection except model 2 of all adverse
events. A higher number of punctures was related with higher risk of pancreatitis but lower
risk of infection. Therefore, the risk of all adverse events was not changed with the number of
punctures. Size of needle, history of surgery, use of protease inhibitor, use of antibiotics, smok-
ing and the size of lesion were related with the risk but they were not consistent in all adverse
events and models (Table 3). The most common puncture site was pancreas, so we analyzed
the risk factors of all adverse events and pancreatitis in 495 patients who experienced pancreas
puncture during EUS-FNA. ERCP on the same day and more than 15 to-and-fro movements
correlated with all adverse events and pancreatitis (Table 4).
Analysis of patients with sufficient information about potentially modifiable details during
EUS-FNA procedures showed that ERCP on the same day [OR = 2.53, 95% CI (1.21, 5.32)]
and normal pancreas puncture [OR = 1.89 CI (1.03, 3.47)] correlated with all adverse events
(S2 Table). Risk factors of pancreatitis in 282 patients who experienced pancreas puncture dur-
ing EUS-FNA were ERCP on the same day [OR = 3.07 CI (1.16, 8.12)], more than 15 to-and-
fro movements [OR = 3.58 CI (1.45, 8.86)], and normal pancreas puncture [OR = 2.78 CI
(1.14, 6.80)] (S3 and S4 Tables).
Incidence of severe adverse events
Severe adverse events occurred in 0.29% (12/4097) of all procedures. Of 45 cases with pancrea-
titis, 3 had severe events: One received an endoscopic cystogastrostomy 4 weeks after
EUS-FNA, and the other two patients were hospitalized for longer than 4 weeks. Four patients
from 46 infection cases required drainage to control. Two infected cysts were drained
Risk factors of EUS-FNA adverse events
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Table 1. Characteristics of the study population (N = 624).
Cases (n = 104) N (%) Controls (n = 520) N (%) P-value
Age (years) [Range 22–94] 62.0 ±12.6 63.3 ±12.7 0.37
Male 55 (52.9) 271 (52.1) 0.89
Alcohol drinkers 28 (26.9) 123 (23.7) 0.48
Smokers 27 (26.0) 109 (21.0) 0.48
Medical history
Pancreatitis 6 (5.8) 16 (3.1) 0.17
Liver cirrhosis 0 3 (0.6) 0.44
Chronic renal failure 0 5 (1.0) 0.32
Cancer 10 (9.6) 51 (9.8) 0.95
Upper GI tract surgery 2 (1.9) 42 (8.1) 0.03
Medication
Antiplatelet 25 (4.8) 2 (1.9) 0.19
Anticoagulant 8 (1.5) 0 0.20
Heparinization 4 (0.8) 0 0.37
Antibiotic 198 (38.1) 42 (40.4) 0.66
Protease inhibitor 38 (7.3) 14 (13.5) 0.04
Nature of lesion 0.40
Solid 79 (76.0) 414 (79.6)
Cystic 25 (24.0) 106 (20.4)
Malignancy 70 (67.3) 351 (67.5) 0.97
Origin of lesion 0.17
Pancreas 90 (86.5) 401 (77.1)
Lymph node 6 (5.8) 59 (11.3)
Sub-mucosal tumor 3 (2.9) 29 (5.6)
Other 5 (4.8) 31 (5.7)
Size of lesion, cm 3.7 ±1.8 3.4 ±1.8 0.09
Vascularity (hypovascular) 95 (91.4) 449 (86.4) 0.22
ERCP on the same day 27 (26.0) 62 (11.9) < 0.01
Previous stent insertion 4 (3.8) 12 (2.3) 0.37
Experience of endoscopists (150) 82 (78.9) 405 (77.9) 0.83
Location of the endoscopic tip 0.23
Esophagus 2 (1.9) 29 (5.6)
Stomach 56 (53.9) 240 (45.2)
Duodenum 44 (42.3) 229 (44.0)
Other 1 (1.0) 3 (0.6)
Missing 1 (1.0) 19 (3.7)
Size of needle 0.04
25 G 19 (18.3) 81 (15.6)
22 G 75 (72.1) 325 (62.5)
19 G 7 (6.7) 82 (15.8)
Unknown 3 (2.9) 32 (6.2)
Type of needle 0.97
Conventional 89 (85.6) 439 (84.4)
TruCut 4 (3.9) 18 (3.5)
Procore 4 (3.9) 21 (4.0)
Unknown 7 (6.7) 42 (8.1)
Number of punctures 2.8 ±1.8 2.6 ±1.36 0.37
(Continued )
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internally with plastic stents and another infected cyst was drained externally with a nasocystic
tube for irrigation. Fourth patient who underwent ERCP on the same day needed ERBD revi-
sion. Two of eight bleeding cases were severe: one needed endoscopic coagulation and the
other underwent angiography and surgical correction. During duodenal intubation one
patient underwent a gastrointestinal perforation that required a surgery for primary closure.
Two severe adverse events from four patients classified as others were an acute cholecystitis
and a pharyngeal perforation. The acute cholecystitis developed during EUS-FNA for gallblad-
der cancer and managed with percutaneous transhepatic gallbladder drainage. The pharyngeal
perforation during oral endoscopic intubation was managed with initial incision and drainage
and delayed surgical repair.
All adverse event cases recovered without mortality.
Discussion
The incidence of adverse events in EUS-FNA was quite low, as expected, in this comprehensive
nationwide retrospective review of medical records in Korea, where EUS-FNA has become
popular. Infection and pancreatitis were most common. Fortunately, clinically severe adverse
events occurred in 0.29% of all cases without mortality. The severe adverse event rate of the
survey in Japan was 0.23%, which is consistent with our results [20].
Table 1. (Continued)
Cases (n = 104) N (%) Controls (n = 520) N (%) P-value
Number of to-and-fro movements 0.05
15 39 (37.5) 261 (50.2)
>15 55 (52.9) 213 (41.0)
Unknown 10 (9.6) 46 (8.8)
Type of adverse event
Pancreatitis 45 (43.3) -
Infection 46 (44.2) -
Bleeding 8 (7.7) -
Perforation 1 (1.0) -
Other 4 (3.9) -
Potentially modifiable details during EUS-FNA procedures (n = 359)†
Normal pancreas puncture 37 (61.7) 141 (47.2) 0.04
Distance between endoscope and target 1.5± 0.9 1.3 ± 0.9 0.09
Straightening 0.65
Yes 39 (65.0) 205 (68.6)
Unknown 2 (3.3) 5 (1.7)
Use of Elevator 0.92
Yes 23 (38.3) 114 (38.1)
Unknown 7 (11.7) 30 (10.0)
Off-targeting, yes 2 (3.3) 3 (1.0) 0.16
Vascular puncture, yes 0 3 (1.0) 0.44
Sonographic bleeding 0.49
Yes 0 5 (1.7)
Unknown 0 2 (0.7)
EUS-FNA: Endoscopic ultrasound-guided fine needle aspiration
Values are mean ± SD or number (%)
†Patients for whom information was available about potentially modifiable details
https://doi.org/10.1371/journal.pone.0189347.t001
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Table 2. Factors associated with EUS-FNA adverse events (Unadjusted).
All adverse events (N = 624) Odds
ratio (95% CI)
Pancreatitis (n = 565) Odds ratio
(95% CI)
Infection (n = 566) Odds ratio
(95% CI)
Age, years 0.99 (0.97, 1.01) 0.98 (0.96, 1.01) 1.00 (0.97,1.03)
Female (reference(ref): male) 0.97 (0.64, 1.48) 0.75 (0.40, 1.40) 0.91 (0.49, 1.70)
Drinking, yes (ref: none) 1.19 (0.74, 1.92) 1.38 (0.70, 2.72) 1.38 (0.69, 2.76)
Smoking, yes (ref: none) 1.32 (0.81, 2.15) 1.09 (0.53, 2.26) 2.07 (1.05, 4.07)*
History (ref: none)
Pancreatitis 1.93 (0.74, 5.05) 1.34 (0.29, 6.25) 2.66 (0.70, 10.10)
Cancer 0.98 (0.48, 2.00) 1.17 (0.43, 3.15) 0.87 (0.29, 2.57)
Surgery 0.22 (0.05, 0.94)* 0.60 (0.14, 2.60) -
Medication (ref: no use)
Medication with bleeding risk† 0.30 (0.07, 1.27) 0.32 (0.04, 2.48) 0.38 (0.05, 2.91)
Antibiotics 1.10 (0.72, 1.69) 3.60 (1.87, 6.94)* 0.45 (0.14, 1.45)
Protease inhibitors 1.97 (1.03, 3.79)* 2.01 (0.83, 4.83) 1.44 (0.28, 7.38)
Nature of lesions, cyst (ref: solid) 1.24 (0.75, 2.03) 1.58 (0.80, 3.13) 1.05 (0.48, 2.29)
Malignancy (ref: benign) 0.99 (0.63, 1.55) 1.07 (0.55, 2.07) 0.89 (0.46, 1.73)
Origin of the lesion (ref: pancreas)
Lymph node 0.45 (0.19, 1.08) 0.15 (0.02, 1.14) 0.81 (0.27, 2.42)
Sub-mucosal tumor 0.46 (0.13, 1.54) n.a. 0.70 (0.16, 3.11)
Other 0.72 (0.27, 1.90) n.a. 1.22 (0.33, 4.42)
Size of lesion, cm 1.09 (0.98, 1.21) 0.89 (0.72, 1.10) 1.20 (1.05, 1.37)*
Vascularity, hypovascular (ref:
hypervascular)
1.90(0.79, 4.55) 1.57 (0.46, 5.31) 2.67 (0.62, 11.50)
ERCP on the same day, yes (ref: none) 2.59 (1.56, 4.32)* 2.82 (1.31, 6.10)* 2.73 (1.35, 5.53)*
Previous stent insertion, yes (ref:
none)
1.69 (0.53, 5.36) 2.79 (0.72, 10.79) 1.52 (0.17, 13.17)
Experience of endoscopists,150
(ref: < 150)
1.06 (0.63, 1.77) 0.83 (0.40, 1.71) 0.64 (0.20, 2.02)
Location of the endoscopic tip (ref:
esophagus)
Stomach 3.38 (0.78, 14.60) n.a. 0.82 (0.27, 2.42)
Duodenum 2.79 (0.64, 12.10) n.a. 0.70 (0.16, 3.11)
Etc. 4.83 (0.33, 70.40) n.a. 1.22 (0.34, 4.42)
Size of needle (ref: 25 G)
22 G 0.98 (0.56, 1.72) 0.61 (0.29, 1.28) 1.18 (0.30, 4.74)
19 G 0.36 (0.15, 0.91)* 0.22 (0.05, 1.10) 0.38 (0.07, 2.15)
Unknown 0.40 (0.11, 1.44) 0.17 (0.02, 1.39) 1.33 (0.20, 8.86)
Type of needle (ref: conventional)
TruCut 1.10 (0.36, 3.32) n.a. 0.66 (0.08, 5.34)
Procore 0.94 (0.31, 2.80) n.a. 1.16 (0.12, 10.91)
Unknown 0.82 (0.36, 1.89) n.a. 1.63 (0.35, 7.74)
Number of punctures 1.07 (0.92, 1.23) 1.24 (1.02, 1.50)* 0.70 (0.51, 0.96)*
To-and-fro movement (ref:1–15)
>15 1.73 (1.10, 2.71)* 2.25 (1.07, 4.73)* 2.74 (1.13, 6.61)*
Unknown 1.45 (0.68, 3.12) 1.51 (0.45, 5.08) 1.60 (0.38, 6.65)
EUS-FNA: Endoscopic ultrasound-guided fine needle aspiration; ERCP: endoscopic retrograde cholangiopancreatography; n.a.: not available
†Antiplatelet drugs, anticoagulants, or heparinization.
*P < 0.05
https://doi.org/10.1371/journal.pone.0189347.t002
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The overall complication rate in this study was 2.5% that seemed to be higher than that of
previous retrospective studies [11,14,21]. In our practice, the patients were observed in
Table 3. Factors associated with EUS-FNA adverse events (Adjusted).
All adverse events (n = 624) Pancreatitis (n = 565) Infection (n = 566)
Model 1† Odds
ratio (95% CI)
Model 2† Odds
ratio (95% CI)
Model 1† Odds
ratio (95% CI)
Model 2‡ Odds
ratio (95% CI)
Model 1† Odds
ratio (95% CI)
Model 2‡ Odds
ratio (95% CI)
ERCP on the same day
(ref: none)
2.58 (1.54, 4.32)* 2.41 (1.41, 4.12)* 2.36 (1.04, 5.32)* 2.31 (1.02, 5.25)* 2.77 (1.36, 5.66)* 2.75 (1.31, 5.78)*
To-and-fro movements
(ref:1–15)
-
>15 1.87 (1.17, 3.01)* 1.57 (0.95, 2.60) 2.87 (1.30, 6.32)* 2.30 (1.11, 4.77)* 2.93 (1.17, 7.30)* 3.65 (1.55, 8.59)*
Unknown 1.43 (0.65, 3.12) 1.76 (0.76, 4.04) 1.48 (0.43, 5.13) 1.24 (0.36, 4.31) 1.43 (0.33, 6.35) 2.13 (0.53, 8.66)
Size of needle (ref: 25
G)
- - - -
22 G 0.95 (0.54, 1.67) 0.88 (0.48, 1.59) - - - -
19 G 0.32 (0.12, 0.81)* 0.35 (0.13, 0.92)* - - - -
Unknown 0.36 (0.10, 1.32) 0.36 (0.09, 1.40)
History of surgery (ref:
none)
0.23 (0.05, 0.96)* 0.20 (0.05, 0.84)*
Protease inhibitor (ref:
no use)
2.03 (1.03, 3.99)* 1.95 (0.94, 4.05)
Number of punctures - - 1.33 (1.08, 1.63)* 1.34 (1.08, 1.67)* 0.69 (0.50, 0.96)* 0.66 (0.48, 0.89)*
Antibiotics (ref: no use) - - 3.36 (1.69, 6.69)* 3.78 (1.82, 7.84)* - -
Smoking, yes (ref:
none)
- - - - 2.25 (1.06, 4.78)* 2.60 (1.17, 5.77)*
Size of lesion, cm - - - - 1.21 (1.05, 1.40) 1.18 (1.01, 1.36)*
EUS-FNA: Endoscopic ultrasound-guided fine needle aspiration; ERCP: Endoscopic retrograde cholangiopancreatography; ref: Reference
† Model 1 adjusted for age, sex, nature of lesion, and experience of endoscopists
‡ Model 2 additionally adjusted for variables that were statistically significant (P < 0.05) in the univariate analysis (Table 2) All adverse events: ERCP on the
same day, to-and-fro movements >15, size of needle, history of surgery, and protease inhibitor; Pancreatitis: ERCP on the same day, to-and-fro movements
>15, number of punctures, and antibiotics; Infection: ERCP on the same day, to-and-fro movements >15, number of punctures, smoking and size of lesion.
*P < 0.05
https://doi.org/10.1371/journal.pone.0189347.t003
Table 4. Risk factors among patients with EUS-FNA to the pancreas† (Adjusted).
All adverse events (n = 491) Pancreatitis (n = 445)
Model 1‡ OR (95% CI) Model 2§ OR (95% CI) Model 1‡ OR (95% CI) Model 2§ OR (95% CI)
Bile duct abnormal (ref: none) 2.35 (1.29, 4.27)* 1.89 (0.98, 3.67)
ERCP on the same day (ref: none) 2.42 (1.40, 4.17)* 1.90 (1.04, 3.46)* 2.56 (1.15, 5.68)* 2.15 (0.93, 4.98)
To-and-fro movements (ref:1–15)
>15 2.13 (1.27, 3.57)* 2.12 (1.25, 3.59)* 2.67 (1.19, 5.96)* 2.47 (1.09, 5.59)*
Unknown 1.63 (0.67, 3.97) 1.74 (0.70, 4.29) 1.70 (0.48, 6.05) 1.43 (0.33, 6.16)
Number of punctures 1.30 (1.05, 1.62)* 1.22 (0.97, 1.53)
†All adverse events (n = 90); pancreatitis (n = 44)
EUS-FNA: Endoscopic ultrasound-guided fine needle aspiration; ERCP: Endoscopic retrograde cholangiopancreatography; ref: Reference
‡ Model 1 adjusted for age, sex, nature of lesion, and experience of endoscopists
§ Model 2 additionally adjusted for variables that were statistically significant (P < 0.05) in the univariate analysis (S2); all adverse events: ERCP on the
same day, to-and-fro movements >15, and bile duct abnormal; pancreatitis: ERCP on the same day, to-and-fro movements >15, and number of punctures
*P < 0.05
https://doi.org/10.1371/journal.pone.0189347.t004
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admission at least for 24 hours after EUS-FNA and we comprehensively collected the data. So,
the complication rate was similar to that of prospective studies [9,10,12,13,21].
This multicenter case-control study collected sufficient events to analyze risk factors,
including endoscopic techniques after comprehensive reviews of the largest number of
EUS-FNA procedures in a single study to date. The major risk factors we found were ERCP on
the same day, a higher number of punctures, and increasing to-and-fro movements during
puncture.
In this study, ERCP following EUS FNA on the same day was associated with higher risk of
adverse events than EUS-FNA alone. Because EUS-FNA and ERCP were usually done together
in practice, it is necessary to assess the risk of ERCP and EUS-FNA simultaneously. However,
no prospective study has assessed the risk of a combined procedure in the same day. There are
only two retrospective observational studies with small number of patients; one study in 2007
reported that a combined procedure might be safe with only 25 patients [22] and the other in
2012 that the complication rate of stent and EUS-FNA seemed not to be higher than that of
stent alone [23]. In the later study, the stent alone group consisted of patients with higher risk
of adverse events (higher American Society of Anesthesiologists score [p = 0.011] and older
age [p = 0.06]). As the ERCP procedures itself carry a high risk of post-procedural adverse
events, further study should be necessary to evaluate the effect of combined procedure on
adverse events.
Higher number of punctures increased the risk of pancreatitis and decreased that of infec-
tion, so it did seem not to correlate with the overall adverse event rate. The puzzling result that
a larger number of punctures was inversely related to the development of infection might stem
from selection bias by indication. In cases with a high risk of infection in the clinical context,
an endoscopist tries to minimize pancreatic puncture numbers, especially into a pancreatic
cyst. Therefore, we found fewer punctures of cysts than of solid masses in this study: 2.9 passes
in solid masses and 1.9 passes in cysts (P< 0.001). Even though cysts have been reported to be
more vulnerable to infection than solid masses [24–26], cyst punctures did not increase risk of
infection in our study, apparently because most institutes followed the rules of cyst aspiration:
complete aspiration if possible and prophylactic antibiotics. Because of those routine proto-
cols, we found no difference according to the nature of lesions. Similarly, the incidence of
infection during cystic punctures in prospective studies using prophylactic antibiotics was low
[16,19,27].
More than 15 to-and-fro movements was a risk factor in pancreatitis and infections but not
in overall adverse events. The other adverse events, except pancreatitis and infections, included
bleeding and duodenal and pharyngeal perforation during intubation. Those adverse events
prevented the endosonographers from performing a higher number of to-and-fro movements;
therefore, we observed more than 15 to-and-fro movements in 15% of those patients, com-
pared with 44% and 74% of patients with pancreatitis and infections, respectively (P = 0.004).
Therefore, more movement was not a risk factor of all adverse events in this study.
These three factors, ERCP on the same day, number of punctures, and number of to-and-
fro movements, might be considered in patients for whom the development of a mild adverse
event might result in a serious problem because of the clinical situation. In such high-risk
patients, ERCP and EUS might be performed on different days, and the endoscopist could try
to limit the numbers of to-and-fro movements and punctures.
We also identified other factors related to overall or specific adverse events: 19G needle use,
history of upper gastrointestinal tract surgery, use of antibiotics, smoking, larger lesions, and
passage through normal pancreas during lesion puncture. Some of those results might have
been caused by bias or confounded by indication. Usually, endosonographers avoid stiff
19-gauge needles in lesions that are more difficult to access and are cautious and less aggressive
Risk factors of EUS-FNA adverse events
PLOS ONE | https://doi.org/10.1371/journal.pone.0189347 December 13, 2017 9 / 13
with patients who have abnormal anatomy. Therefore, use of a 19G needle and a history of sur-
gery negatively correlated with adverse events. Moreover, there were only 12 EUS-FNA done
to patients with the altered anatomy among 44 patients who underwent surgeries. This could
be another reason of negative correlation between a history of upper abdominal surgery and
adverse events after EUS-FNA. Clinicians are more likely to administer antibiotics to patients
with a higher risk of adverse events, so use of antibiotics is positively related to development of
adverse events.
We analyzed the size as a continuous variable and it didn’t relate with any adverse events.
Katanuma A et al reported that the incidence of adverse events after EUS-FNA was signifi-
cantly increased in small tumors (20 mm) [28] but there was no statistical difference when
we assess whether tumor 20 mm or less were a risk factor. (Control: Case = 35.9%: 26.5%
p = 0.07)
Another limitation of this study was that there were considerably missing variables, which
could bias the actual risk. To overcome it, we analyzed the data after excluding patients with
missing variables to assess whether those variables were risk factors. In that analysis, we found
new risk factors consistent with that of all patients. One of them was passage through the nor-
mal pancreas to puncture the lesion which increased the risk like a previous report [15]. And,
pancreatic trauma is a well-known etiology of pancreatitis.
From this study, we found some risk factors might be associated with complication of
EUS-FNA. The results of our study would be helpful for endoscopists to perform safer
EUS-FNA. Further prospective study would be necessary to determine risk factors of
EUS-FNA.
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